C. Bakker, R.
Bastiaannet, R.
van Nimwegen, S. A.
D. Barten-van Rijbroek, A.
Van Es, R. J. J.
Rosenberg, A. J. W. P.
de Jong, H. W. A. M.
Lam, M. G. E. H.
Nijsen, J. F. W.
Funding for this research was provided by:
Dutch Cancer Society (7075-2014)
Article History
Received: 26 July 2019
Accepted: 26 March 2020
First Online: 11 May 2020
Ethics approval and consent to participate
: Institutional Review Board approval was obtained (see the “Methods” section).Approval from the institutional animal care committee was obtained (see the “Methods” section).
: Written informed consent was obtained from all patients in this study.
: The authors of this manuscript declare relationships with the following companies: BTG, Quirem Medical BV, and Terumo. J.F.W. Nijsen is co-founder and scientific director of Quirem Medical and has a minority share in the company Quirem Medical. Furthermore, Nijsen is inventor on the patents related to the 166Ho-PLLA-microspheres that are assigned to University Medical Center Utrecht Holding BV (patent numbers: WO2012060707 A1 and US 2005/0201940 A1). The Department of Radiology and Nuclear Medicine of the UMC Utrecht receives royalties from Quirem Medical BV. M.G.E.H. Lam is a consultant for BTG, Quirem Medical BV, and Terumo. The Department of Radiology and Nuclear Medicine of the UMC Utrecht receives royalties from Quirem Medical BV.